APR Applied Pharma Research
APR Applied Pharma Research is a Swiss pharmaceutical company (wholly owned by Relief Therapeutics) that develops and commercializes patent-protected branded products in niche and rare disease areas, including PKU dietary management, advanced wound care, cancer supportive care, and rare dermatological/ocular conditions, selling through direct European sales and a partner network spanning 70+ countries.
- Company typePrivate
- Founded1990
- HeadquartersBalerna, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What APR Applied Pharma Research does
APR Applied Pharma Research s.a. is a Swiss pharmaceutical company headquartered in Balerna, Ticino, Switzerland, and a wholly owned subsidiary of Relief Therapeutics Holding AG (SIX: RLF.SW). Founded in 1990, the company identifies, develops, and commercializes patent-protected prescription and consumer healthcare products in niche and rare therapeutic areas, with a stated focus on inherited metabolic disorders (Phenylketonuria), advanced wound care, cancer supportive care, acute pain/migraine, and rare dermatological and ocular diseases.
The product portfolio is built on four proprietary technology platforms. Physiomimic Technology underpins the PKU GOLIKE family (Plus, KRUNCH, BAR) of phenylalanine-free amino acid formulations for PKU dietary management, using a coated-granule architecture that delivers gradual, prolonged release over up to 7 hours and masks taste/odor. Tehclo Technology is a patented hypochlorous-acid nanotechnology platform used in Nexodyn AcidOxidizing Solution (a Class III EU medical device) for chronic wound care, and is also being applied to pipeline assets for Epidermolysis Bullosa (APR TD011), Hailey-Hailey Disease (APR TD012), and ocular surface diseases (APR 1204). Dynamic Buffering Technology enables an immediate-release Diclofenac K formulation with faster onset; Oral Dispersible Film (ODF) technology powers Setofilm (Ondansetron) for cancer supportive care. Consumer brands include Halykoo (pediatric OTC) and SwitzAGE (healthy aging nutraceuticals).
APR operates a dual business model. First, it generates product revenue through a mix of direct sales teams in Italy, Germany, Switzerland, and Austria, combined with an extensive network of commercial partners reaching over 70 countries (with named third-party distributors for Spain and the UK). Second, it provides contract development services to third-party pharmaceutical companies on a fee-for-service basis across solid, non-solid, and analytical services. Revenue and pricing details are not publicly disclosed; the company is GMP-, GDP-, and ISO 13485-certified (Swissmedic / TÜV SÜD) and holds authorization for handling controlled substances.
APR Applied Pharma Research firmographics
Firmographics- Name
- APR Applied Pharma Research
- Legal name
- APR Applied Pharma Research s.a.
- Website
- http://www.apr.ch/applied-pharma-research/
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- APR Applied Pharma Research is a Swiss pharmaceutical company (wholly owned by Relief Therapeutics) that develops and commercializes patent-protected branded products in niche and rare disease areas, including PKU dietary management, advanced wound care, cancer supportive care, and rare dermatological/ocular conditions, selling through direct European sales and a partner network spanning 70+ countries.
- Ownership category
- akta.pro rank
APR Applied Pharma Research industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where APR Applied Pharma Research is headquartered
LocationHeadquarters
- HQ city
- Balerna
- HQ country
- Switzerland
- HQ region
- Europe
Offices6 records
Markets served
APR Applied Pharma Research business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: APR generates revenue from a balanced portfolio of revenue-generating branded products marketed in all major markets, including prescription healthcare products (PKU GOLIKE, Nexodyn, Diclofenac, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE).
- Contract R&D Services: Provides added-value R&D services under contract and on a fee-for-service basis including research and development services, complete project supervision, management and execution, development of oral and topical formulations and customized drug delivery technologies.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels3 records
APR Applied Pharma Research product offering
Product offeringCore offering
APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes patent-protected, science-driven products in niche and rare therapeutic areas. It markets branded prescription healthcare products (PKU GOLIKE family, Nexodyn, Diclofenac IR, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE), and additionally provides contract R&D and formulation development services on a fee-for-service basis.
Product overview
APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes best-in-class, patent-protected products in selected rare and ultra-rare disease areas. The company's product portfolio is built on proprietary technology platforms and includes prescription healthcare products and consumer healthcare products. The main marketed products include: PKU GOLIKE family (Plus, KRUNCH, and BAR) - food for special medical purposes for Phenylketonuria dietary management powered by Physiomimic Technology; Nexodyn AcidOxidizing Solution - advanced wound cleanser powered by Tehclo Technology; Diclofenac Immediate Release - for migraine and acute pain using Dynamic Buffering Technology; Setofilm - oral film Ondansetron for cancer supportive care using ODF technology; and consumer products including Halykoo pediatric range and SwitzAGE nutraceuticals. APR also provides contract development and manufacturing services (CDMO) to the pharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Brands
- PKU GOLIKE: Innovative food for special medical purposes (FSMP) consisting of Phe-free amino acid mixture for Phenylketonuria dietary management, powered by Physiomimic Technology
- Nexodyn
- Setofilm
- Halykoo
- SwitzAGE
Products and services
- PKU GOLIKE Plus
Quantifiable outcome
- Prolonged amino acid release up to 7 hours
- +4 more outcomes
Companies that use APR Applied Pharma Research
Customer profileSegments6 records
Ideal customer profiles4 records
APR Applied Pharma Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
APR Applied Pharma Research partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- APR Applied Pharma Research - Italy S.r.l.coreEU representative and exclusive distributor of PKU GOLIKE products for Italy. Located in Rome with operations in Monza.
- APR Applied Pharma Research - Deutschland GmbHcoreDistributor for PKU GOLIKE products in Germany, Austria, and Switzerland. Located in Offenbach, Germany.
- Rendon Europe Laboratories S.L.majorDistributor for PKU GOLIKE products in Spain. Located in Madrid, Spain.
- Meta Healthcare LTDmajorDistributor for PKU GOLIKE products in the UK. Located in Hemel Hempstead, United Kingdom.
- Global Pharmaceutical PartnersmajorExtensive network of partnerships with pharmaceutical companies internationally sized for distribution in over 70 countries worldwide.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
APR Applied Pharma Research competitors and assessment
Company assessmentDirect peers
- BioMarin Pharmaceutical: Specialty/rare-disease biotech with the most relevant overlap in PKU therapeutics (Kuvan, Palynziq). Operates in the same niche rare metabolic indication with proprietary formulation approaches, making it the closest functional peer to APR's PKU GOLIKE franchise.
- ConvaTec: Global medical products company with a sizable Advanced Wound Care business (AQUACEL, InnovaMatrix). Competes head-to-head with Nexodyn AOS in advanced wound management and shares focus on chronic, hard-to-heal wounds.
- Recordati Rare Diseases: European specialty pharma with an explicit Rare Diseases business unit covering metabolic, endocrine, and ultra-rare indications. Closely comparable in therapeutic-area focus, European commercial model, and emphasis on patented niche products.
- Nestlé Health Science: Through its Vitaflo and broader medical nutrition portfolio, Nestlé Health Science is a leading provider of PKU medical foods and low-protein nutritional products. Directly competes with the PKU GOLIKE range in diet management of phenylketonuria.
- Nutricia (Danone): Nutricia's Metabolic and Rare Disease unit supplies amino acid-based medical foods for PKU and related inherited metabolic disorders across Europe. Direct overlap with APR's PKU GOLIKE Plus, KRUNCH and BAR formulations in phenylketonuria dietary management.
- Sobi (Swedish Orphan Biovitrum): Specialty biotech dedicated to rare diseases (haematology, immunology, specialty care) with European commercial footprint. Comparable as a focused rare-disease commercializer operating globally in specialty/rare indications.
- Ajinomoto Health & Nutrition (formerly Cambrooke Therapeutics): Acquired Cambrooke Therapeutics, a focused PKU and rare metabolic disorder medical food company providing amino acid formulas comparable to PKU GOLIKE. Direct competitor in the inherited metabolic disease dietary management category.
Broad incumbents
- Almirall: European specialty pharma with a dermatology-led portfolio including rare/skin disease treatments. Comparable to APR in targeting niche dermatology (Epidermolysis Bullosa, Hailey-Hailey) with proprietary formulations, though Almirall is significantly larger and broader.
- Chiesi Farmaceutici: Privately held European pharma with established rare disease franchises (e.g., haemophilia, lysosomal storage disorders). Overlaps in rare disease specialty therapeutics and proprietary respiratory/specialty delivery platforms, though much broader in portfolio scale than APR.
- Smith & Nephew: Large diversified wound care franchise with advanced and surgical wound management products serving hospitals and home care. Overlaps with APR's Nexodyn chronic wound strategy at a much broader global scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
APR Applied Pharma Research social profiles
Digital presenceAPR Applied Pharma Research compliance and trust
Trust signalCompliance4 records
APR Applied Pharma Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
APR Applied Pharma Research leadership team
Management profileNumber of profiles
Profiles1 record
APR Applied Pharma Research subsidiaries and ownership
Company hierarchySubsidiaries2 records
APR Applied Pharma Research funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
APR Applied Pharma Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about APR Applied Pharma Research
What does APR Applied Pharma Research do?
APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes patent-protected, science-driven products in niche and rare therapeutic areas. It markets branded prescription healthcare products (PKU GOLIKE family, Nexodyn, Diclofenac IR, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE), and additionally provides contract R&D and formulation development services on a fee-for-service basis.
Is APR Applied Pharma Research a public or private company?
APR Applied Pharma Research is a private company. It is classified as corporate owned and is currently operating.
When was APR Applied Pharma Research founded?
APR Applied Pharma Research was founded in 1990. It employs 11 to 50 people.
Where is APR Applied Pharma Research based?
APR Applied Pharma Research is headquartered in Balerna, Switzerland, in the Europe region.
How does APR Applied Pharma Research make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract R&D Services.
Who are APR Applied Pharma Research's main competitors?
Direct peers on record are BioMarin Pharmaceutical, ConvaTec, Recordati Rare Diseases, Nestlé Health Science, Nutricia (Danone), Sobi (Swedish Orphan Biovitrum) and Ajinomoto Health & Nutrition (formerly Cambrooke Therapeutics). Broad incumbents are Almirall, Chiesi Farmaceutici and Smith & Nephew.
Does APR Applied Pharma Research have an API?
No public API is recorded for APR Applied Pharma Research.
What industry is APR Applied Pharma Research in?
APR Applied Pharma Research's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 3254 and its SIC code is 2834.